ClinicalTrials.gg
RecruitingNCT05776095Updated Feb 2, 2024

Evaluation of Safety and Performance Outcomes of Eyedeal IOL Implantation After Cataract Removal

An interventional study of Cataract surgery and Eyedeal® Model PX65AS1 IOL in Lens Implantation, Intraocular, sponsored by Xi'an Eyedeal Medical Technology Co., Ltd. Recruiting at 2 sites in 2 countries. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2024-02-02.

Sponsored by Xi'an Eyedeal Medical Technology Co., Ltd · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 8 months ago, but the record still lists the study as recruiting.
  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
97
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies in Cataract with a site in Germany — 8 open to participants now, 11 under way, none of them phase 3. Cataract · Germany.

Planned enrollment
24th of 50
97 · median 95
Started
2023
with 4 others
No phase
35 of 61
6 open now
Primary completion
2025-02
later than 1 of 10 live
Registered
49th of 61
by date

Among the 61 studies in Cataract with a site in Germany, this one is the 24th largest by planned enrollment of the 50 interventional ones that give a count, is one of 5 that started in 2023, is one of 35 with no phase, reaches primary completion later than 1 of the 10 other live ones, and was the 49th registered.

Cataract

1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.

Browse Cataract studies →

Open to participants now

8 of the 61 studies in Cataract with a site in Germany are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Cataract with a site in Germany, or all of them as a file.
02

Study summary

A cataract is the clouding of the natural lens in the eye and is very common as when getting older. A cloudy lens makes it difficult to see. A cataract is treated by removing the cloudy lens and replacing it with an intraocular lens (known as an IOL). The goal of this clinical trial is to determine if the Eyedeal® IOL can be safely implanted in a subject's eye and if it can replace efficiently the natural lens.

Subjects will be asked to attend a total of seven visits for this study for a period of 12 months after surgery.

Read the detailed description

To investigate the safety and performance of the Eyedeal® PX65AS1 intraocular lens (IOL)

  • To evaluate the safety profile with regards to best-corrected visual acuity, and adverse events
  • To evaluate the performance with regards of best corrected distance VA after the device implantation

The Eyedeal® IOL (PX65AS1) is a foldable single-piece ultra-violet absorbing posterior chamber intraocular lens (IOL). It is an optical implant to replace the human crystalline lens in the visual correction of aphakia in adult patients after cataract removal. The Eyedeal® PX65AS1 IOL lens is made of a high refractive index soft cross-linked polyolefin. The Eyedeal® PX65AS1 IOL lens has an aspheric optic with symmetric optic design and spherical neutral and correct lens's own spherical aberration supporting haptics to provide proper position of the IOL optic within the capsule.

03

Conditions studied

  • Lens Implantation, Intraocular

Browse trials for

Keywords

  • Cataract
  • Intraocular lens
  • IOL
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults (22 years of age or older at the time of surgery) of any gender and race, diagnosed with age related cataracts in one eye.
  2. Preoperative best corrected distance visual acuity (BCDVA) of 20/32 or worse.
  3. Projected postoperative BCDVA 0.20 logMAR or better in the study eye, as determined by Investigator's medical judgment.
  4. Calculated spherical power targeted at emmetropia at distance in the study eye.
  5. Calculated lens power within the available range for the Eyedeal® Model PX65AS1 IOL (+0.50D - +34.00D).
  6. Planned cataract removal by phacoemulsification procedure.
  7. Clear intraocular media other than cataract, in the study eye.
  8. Pharmacologically dilated pupil size of at least 6.0mm.
  9. 2.0 D or less of preoperative astigmatism in the study eye.
  10. Willing and able to complete all required postoperative visits.
  11. Able to comprehend and sign or through a representative, with a witness present, a statement of IRB or EC approved Form (ICF).

Exclusion criteria

Exclusion Criteria:

  1. Any type of cataract (e.g., traumatic, congenital, polar) other than those noted in inclusion criteria.
  2. Ocular conditions which could affect the stability of the IOL (e.g., pseudoexfoliation, zonular dialysis, evident zonular weakness or dehiscence, etc.) in the study eye.
  3. Any anterior segment pathology likely to increase the risk of complications from phacoemulsification cataract extraction (e.g., chronic uveitis, iritis, iridocyclitis, aniridia, rubeosis iridis, corneal disorders, (Fuch's, or anterior basement membrane dystrophy, etc.) in the study eye.
  4. Mature cataract that is likely to prolong phacoemulsification and/or lead to intraoperative complications prior to attempted IOL implantation.
  5. Any visually significant intraocular media opacity other than cataract in the study eye.
  6. History of any clinically significant retinal pathology or ocular diagnosis (e.g., diabetic retinopathy, ischemic disease, macular degeneration, retinal detachment, amblyopia, optic neuropathy, microphthalmos, aniridia, neuro-ophthalmic disease, fixation problems etc.) in the study eye that could alter or limit final postoperative visual prognosis.
  7. History of any intraocular, retinal, corneal or refractive surgery in the study eye (including LASIK, PRK, LRI, etc.).
  8. History of cystoid macular edema in the study eye.
  9. History of serious corneal disease (e.g., herpes simplex, herpes zoster keratitis, etc.) in either eye.
  10. Severe dry eye that, in the opinion of the investigator, would impair the ability to obtain reliable study measurements.
  11. Uncontrolled glaucoma and/or optic atrophy in the study eye.
  12. Subjects with large refractive errors (hyperopia/myopia) of axial or pathologic origin that, in the opinion of the investigator, could confound outcomes.
  13. Abnormal corneal findings in either eye (e.g. keratoconus, pellucid marginal degeneration, or irregular astigmatism).
  14. Uncontrolled systemic disease (e.g., diabetes mellitus, active cancer treatment, mental illness, etc.) in the opinion of the investigator, would put the subject's health at risk and/or prevent the subject from completing all study visits.
  15. Systemic medication that, in the opinion of the investigator, may confound the outcome or increase the intraoperative and post-operative risk to the subject (e.g., tamsulosin hydrochloride) or other medications including anticholinergics, alpha adrenergic blocking agents with similar side effects (e.g., small pupil/floppy iris syndrome).
  16. Subjects who may reasonably be expected to require any additional ophthalmic surgical intervention at any time during the study (other than YAG capsulotomy).
  17. Need for concomitant procedures (e.g., glaucoma surgery, LRI, RK, LASIK, etc.).
  18. Fellow eye BCDVA worse than 1.0 logMAR.
  19. Extremely shallow anterior chamber (\< 2.0 mm).
  20. Participation in any other drug or device clinical trial within 30 days prior to enrolling this study and/or during study participation.
  21. Pregnancy or lactation.
  22. Subject who, in the judgment of the clinical investigator, is not suitable for participation in the study for any clinical reason, as documented by the investigator on the patient's Case Report Forms - CRFs).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
97 participants (estimated)

Study arms

  • Experimental
    Eyedeal® IOL

    Eyedeal® Model PX65AS1 IOL

    Procedure: Cataract surgery · Device: Eyedeal® Model PX65AS1 IOL

Interventions

  • ProcedureCataract surgery

    Subjects will undergo surgery to remove cataract (the cloudy lenses) via phacoemulsification, and implant the Eyedeal® Model PX65AS1 IOL in the eye capsule.

  • DeviceEyedeal® Model PX65AS1 IOL

    Subjects will undergo surgery to remove cataract (the cloudy lenses) via phacoemulsification, and implant the Eyedeal® Model PX65AS1 IOL in the eye capsule.

06

What researchers measure

Primary outcomes

  1. EFFICACY OUTCOME MEASURE - Uncorrected Distance Visual Acuity

    Uncorrected distance Visual Acuity is measured in accordance with ISO 11979-7:2018 - Appendix E: BCVA 20/40 or better in 95% of cases. The stability and consistency of visual results will be measured over time.

    Time frame: 12 months

  2. SAFETY OUTCOME MEASURE - Best Corrected Visual Acuity

    The safety of the Eyedeal® Model PX65AS1 IOLs (Xi'an Eyedeal Medical Technology Co., Ltd.) will be measured by the following criteria: Loss of BCDVA measured in accordance with ISO 11979-7:2018-Appendix E

    Time frame: 12 months

  3. SAFETY OUTCOME MEASURE - Evaluation of Patient record

    The safety of the Eyedeal® Model PX65AS1 IOLs (Xi'an Eyedeal Medical Technology Co., Ltd.) will be measured by the following criteria: Patient record of inflammation, discomfort, or pain following surgery related to the Eyedeal® Model PX65AS1 IOL (Xi'an Eyedeal Medical Technology Co., Ltd.) . .

    Time frame: 12 months

  4. SAFETY OUTCOME MEASURE - Evaluation of Adverse Events

    The safety of the Eyedeal® Model PX65AS1 IOLs (Xi'an Eyedeal Medical Technology Co., Ltd.) will be measured by the following criteria: Evaluation of all adverse events, adverse device effects and device deficiencies at post-operative examinations

    Time frame: 12 months

07

Study locations

1 of 2 sites recruiting
  • University Eye Clinic Heidelberg
    Heidelberg, Baden-Wuerttemberg 69120, Germany
    Not yet recruiting
    • Raquel Willrich Amroussi, MA · Contact
    • Prof. Dr. med. Gerd U. Auffarth, MD PHD · Principal investigator
  • Department of Ophthalmology, Hospital of Lithuanian University of Health Sciences Kauno klinikos
    Kaunas, 50161, Lithuania
    Recruiting
    • Eglė Karinauskė, MD · Contact
    • Prof. Reda Žemaitienė, MD, PHD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Feb 2025, 15 months after the start.

Of 190 industry-sponsored interventional studies with no phase under Cataract, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 28. This study's planned 15 months is close to that.

Counting every sponsor, half of 494 studies reached it within 17 months; a quarter within 9 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2023
First posted
Mar 20, 2023
StartActual
Nov 10, 2023
Primary completionEst.
Feb 28, 2025
CompletionEst.
Feb 28, 2025
Last update
Feb 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05776095
Lead sponsor
Xi'an Eyedeal Medical Technology Co., Ltd
Responsible party
Sponsor
First posted
Mar 20, 2023
Start date
Nov 10, 2023
Primary completion
Feb 28, 2025 (estimated)
Completion
Feb 28, 2025 (estimated)
Last update
Feb 2, 2024

Study contacts

Q. Trin Peng, MD
Contact
info@eyedeal.com
+86 029 848 88888
Gerd Auffarth, Prof
principal investigator · University Eye Clinic Heidelberg

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion